GlassScriptPhysician profile
Derin Colvin
NPI 1346989944
$5,122.32
in general payments reported to CMS, 2019-2025
24 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $345 · 2023: $1,482 · 2024: $3,127 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,716 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,715.85 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,077.48 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $512.84 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $503.41 | 2022-2024 | Caplyta |
| Corium, LLC | $481.21 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $426.09 | 2022-2024 | Rexulti, Nuedexta |
| Lundbeck LLC | $385.34 | 2022-2025 | Rexulti |
| Alkermes, INC. | $260.66 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $239.39 | 2022-2025 | Sunosi, Auvelity |
| Neurocrine Biosciences, INC. | $205.08 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $172.41 | 2022-2024 | Trintellix |
| Almatica Pharma LLC | $168.44 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $144.39 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $108.72 | 2023-2024 | Fanapt, Hetlioz |
| Vertical Pharmaceuticals, LLC | $77.04 | 2023-2024 | Relexxii |
| Ironshore Pharmaceuticals INC. | $71.60 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61.77 | 2022-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $60.90 | 2023-2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $50.38 | 2022-2023 | Quviviq |
| Avion Pharmaceuticals | $24.02 | 2023 | Methylphenidate Hydrochloride |
| Biogen, INC. | $22.63 | 2024 | |
| Tempus Ai, INC | $19.27 | 2024 | Tempus Pixel |
| Sunovion Pharmaceuticals INC. | $18.30 | 2022 | |
| Harmony Biosciences LLC | $17.82 | 2024 | |
| Noven Therapeutics, LLC | $13.13 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derin Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.